Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05451043
Title Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Cross Cancer Institute RECRUITING Edmonton Alberta Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field